| Range: | 7.995-17.02 | Vol Avg: | 67735 | Last Div: | 0 | Changes: | -0.32 |
| Beta: | 1.45 | Cap: | 0.78B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 20 2023 | Empoloyees: | 61 | ||
| CUSIP: | CIK: | 0001956827 | ISIN: | US00370M1036 | Country: | US | |
| CEO: | Mr. Marc M. P. de Garidel M.B.A. | Website: | https://www.abivax.com | ||||
ABVX 0.00 Stock Price Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow